Mesoblasts share price gained another 16% in July. Heres why. – Motley Fool Australia

Motley Fool Australia Share Market News Mesoblasts share price gained another 16% in July. Heres why.

Bernd Struben | August 7, 2020 2:07pm | More on: MSB ASX 200

Biotechnology company Mesoblast limiteds (ASX: MSB) share price added to the strong gains it notched up from April through June, closing up another 16.3% in July. An impressive performance considering the S&P/ASX 200 Index (ASX: XJO) only gained 0.5% in July.

Mesoblasts share price was hammered badly in the wider market sell-off during early COVID-19 lockdown measures, tumbling a gut-wrenching 60% from 23 February through its low on 24 March.

Since its 23 March low, Mesoblasts share price has come roaring back, up 241% by 31 July.

Year-to-date Mesoblasts share price is up 115%, giving the company a market cap of $2.6 billion.

Mesoblast is a regenerative medicine company developing treatments for inflammatory ailments, cardiovascular disease and back pain.

Mesoblast uses its proprietary technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex diseases. The company targets diseases that are resistant to a conventional standard of care and where inflammation plays a central role.

Mesoblast has four phase-3 products nearing registration:

Mesoblasts share price benefited from the companys involvement in treating COVID-19.

In the first week of July, Mesoblast released a promising update on its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L.

The company reported an expanded access protocol (EAP) had been initiated in the United States for the compassionate use of remestemcel-L. Patients who tested positive for the virus aged between 2 months and 17 years with pre-existing cardiovascular issues could access remestemcel-L within 5 days of referral under the EAP.

Mesoblasts financial performance has also been strong. The company recorded a 113% increase in overall revenues for the first 9 months of the 2020 financial year, compared to the first 9 month of the 2019 financial year. Mesoblasts balance sheet was also fortified by a $138 million fund raising in May. The companys next earning report is scheduled to be released on 27 August.

Mesoblasts share price has continued to run higher, up 16% so far in August.

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Bernd Struben earned his economics degree in the US. Following several years writing about the tourism industry in the Caribbean, he moved to The Netherlands to cover the EUs booming commercial real estate markets. He moved to Australia in 2010, where he transitioned to analysing the Aussie equity markets. He employs a combination of macro economics and company specific data to gauge what he believes are tomorrows best investments. In his free time, youre likely to find Bernd at the beach or dabbling away on a new work of science fiction.

Read this article:
Mesoblasts share price gained another 16% in July. Heres why. - Motley Fool Australia

Future Technological Prospects of Stem Cell Assay Market To 2030 – Owned

The research report published by PROPHECY MARKET INSIGHTS encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Stem Cell Assay market over the forecast period (2019-2029).

The predictions mentioned in the Stem Cell Assay market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Stakeholders Benefit:

The report on the Stem Cell Assay market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3910

We dont know what lies ahead of this COVID-19 Pandemic crises. Our analysis involves the detailed study of the market taking into consideration the impact pandemic situation. We will be grateful if you get in touch with us so that we can understand your exact requirement and we can provide you an exhaustive coverage of the impact of the current situation on the market. We also provide a customized report as per your requirement.

Segmentation Overview:

Global Stem Cell Assay Market, By Type:

Global Stem Cell Assay Market, By Kit:

Global Stem Cell Assay Market, By Detection:

Global Stem Cell Assay Market, By Instruments:

Global Stem Cell Assay Market, By Application:

Global Stem Cell Assay Market, By End User:

The Stem Cell Assay research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Stem Cell Assay market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Regional and Country- level Analysis:

Different geographical areas are studied deeply and an economic scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Request discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/3910

Key Questions Answered in Report:

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Stem Cell AssayMarket Key Players:

GE Healthcare, Promega Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix, STEMCELL Technologies Inc., Bio-Rad Laboratories Inc., R&D Systems Inc., and Cellular Dynamics International Inc.

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Read this article:
Future Technological Prospects of Stem Cell Assay Market To 2030 - Owned

Biobanks Market Projected to be Resilient During 2025 Owned – Owned

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market includeBioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original:
Biobanks Market Projected to be Resilient During 2025 Owned - Owned

Training neural circuits early in development improves response, study finds – University of Illinois News

CHAMPAIGN, Ill. When it comes to training neural circuits for tissue engineering or biomedical applications, a new study suggests a key parameter: Train them young.

Techniques for training engineered neural circuits usually involve training them after the cells have fully matured. Using light-sensitive neurons derived from mouse stem cells, researchers at the University of Illinois, Urbana-Champaign found that training them throughout early cell development and network formation led to lasting improvements in the connections, responsivity and gene expression of the resulting neural network. They published their results in the journal Scientific Reports.

Its like an old dog learning new tricks versus a young puppy, said graduate student Gelson Pagan-Diaz, the first author of the study. When were training a network, if we stimulate it when its still like a puppy, we can get a better response to the training than if it were already mature.

Improved neural training has many applications in bioengineering and regenerative medicine. For example, the Illinois team hopes to use trained neural circuits to control the movement and behavior of miniature bio-hybrid machines. The types of improvements yielded by early training could give the machines and circuits more functionality and give the researchers more precise control over those functions.

As we advance the field of building machines with living cells, being able to stimulate and program neuronal cells and networks with light early in their development could be an important tool in our engineering repository, said study leader Rashid Bashir, a professor of bioengineering and dean of the Grainger College of Engineering at Illinois. Furthermore, this work could have implications for developmental biology, regenerative medicine and brain research.

To train the neurons, the researchers used timed pulses of light to stimulate the cells. The researchers began the training regimen when the cells were early in their development clusters of stem cells, called embryoid bodies, primed to become motor neurons. They continued the training as the cells differentiated, becoming fully mature neurons, and further continued it after transferring the cells to plates to connect and form neural circuits.

They then compared the early trained circuits with those cultured first and trained later the usual method.

The researchers saw a number of differences between the groups, Pagan-Diaz said. In the neurons trained during development, they saw more extensions indicating connections between cells, an increase in neurotransmitter packages sent between cells, and more structured nerve firing, indicating greater network stability. The effects of the early training were long-lasting, whereas cells trained later tended to have transient responses.

You can think of the neurons being like athletes in training, Pagan-Diaz said. The light stimulation was like a regular workout for the neurons they were stronger and more athletic, and did their jobs better.

To determine the underlying basis for these changes, the researchers analyzed the neurons genetic activity. They saw an increase in gene expression for genes related to network maturity and neural function, indicating that the early training could have permanently altered genetic pathways as the cells developed, Bashir said.

The researchers are continuing to explore what kinds of activities could be enhanced or programmed by early neuron training in the embryoid body phase. Embryoid bodies could be useful building-block components for biological machines, Pagan-Diaz said, and also hold promise for regenerative medicine.

Previous studies have shown that embryoid bodies with motor neurons implanted into mice that had been injured could improve the regeneration of tissue, Pagan-Diaz said. If we can improve or enhance the functionality of these embryoid bodies prior to putting them into an injured model, then theoretically we could enhance the recovery beyond what has been seen with injecting them and then stimulating them later.

The National Science Foundation supported this work through the Emergent Behaviors of Integrated Cellular Systems science and technology center and through the Miniature Brain Machinery Research Traineeship. Research staffer Jenny Drnevich, graduate students Karla Ramos-Cruz and Richard Sam, and University of Illinois, Chicago bioengineering professor Perijat Sengupta were co-authors of the paper.

See more here:
Training neural circuits early in development improves response, study finds - University of Illinois News

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 – GlobeNewswire

August 06, 2020 09:00 ET | Source: Alliance for Regenerative Medicine

Cell, Gene & Tissue-Based Therapy Developers Poised to Break Year-Over-Year Global Financing Records

WASHINGTON, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, Innovation in the Time of COVID-19. The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.

As the voice of the sector globally, ARM regularly publishes sector data reports to showcase clinical and scientific progress, as well as advancements and remaining challenges in the policy environment surrounding cell, gene and tissue-based therapies. The report also includes updated metrics on fundraising and clinical trials from more than 1,000 therapeutic developers worldwide.

Highlights from the H1 2020 Global Sector Report include:

Janet Lambert, CEO of ARM, commented:The regenerative medicine and advanced therapy sector has shown remarkable resilience in the face of many new challenges posed by COVID-19. Most importantly, were continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. ARM will continue to work with our membership and with policymakers in the second half of 2020 to further advance these transformative technologies. We are committed to bringing these life-changing therapies to patients in need.

This report is the latest in ARMs series of global regenerative medicine sector reports, providing up-to-date metrics on financings and the clinical landscape, as well as expert commentary on key trends and progress in the field. The full report is availableonline here, with key sector metrics and infographicsavailable here. For more information, please visitwww.alliancerm.orgor contact Kaitlyn (Donaldson) Dupont atkdonaldson@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the voice of the sector, representing the interests of 360+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Excerpt from:
New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - GlobeNewswire

Contract Manufacturing Services market for stem cells is expected to be worth over USD 2.5 billion by 2030, claims Roots Analysis – Market Research…

Driven by a robust and growing pipeline of stem cell therapies, the demand for development and manufacturing services for such advanced product candidates is anticipated to increase beyond the capabilities of innovator companies alone

Roots Analysis has announced the addition of the Stem Cell Contract Manufacturing Market, 2019-2030 report to its list of offerings.

Owing to a highly regulated production environment and the need for state-of-the-art technologies and equipment, it is difficult for innovators to establish in-house expertise for the large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers are increasingly relying on contract manufacturing organizations (CMOs) for their product development and manufacturing needs.

To order this 300+ page report, which features 120+ figures and 145+ tables, please visit this link

Over 80 CMOs presently claim to provide manufacturing services for stem cells therapies The market landscape is fragmented, featuring a mix of companies of all sizes; however, small and mid-sized companies represent 70% of the overall number of industry stakeholders. It is worth highlighting that over 50% of the CMOs claim to be capable of accommodating both clinical and commercial scales of operation.

100+ strategic alliances have been inked since 2015 In fact, nearly 60% of the abovementioned deals were established post 2016. Majority of these agreements were observed to be focused on the manufacturing of various types of stem cells. It is worth highlighting that the maximum number of partnerships related to stem cell therapies were reported in 2018.

More than 80,000+ patients were reported to have been enrolled in stem cell therapy related trials, since 2010 As a result, the manufacturing demand for such therapies can be anticipated to grow significantly over the next decade. The report features detailed projections of the future clinical and commercial demand for stem cell manufacturing, based on parameters, such as target patient population, dosing frequency, dose strength, source of stem cells, type of stem cells and key geographies.

Currently, there are more than 100 facilities dedicated to stem cell manufacturing The maximum share of the installed capacity belongs to large (more than 1,000 employees) and very large (more than 5,000 employees) companies. The report provides a detailed capacity analysis, taking into consideration the reported manufacturing capacities of industry stakeholders, and offering estimates on the distribution of the global contract manufacturing capacity for stem cell therapies, by company size, scale of operation and geography.

By 2030, North America and Europe are anticipated to capture over 70% of the market share Overall, the market is anticipated to witness an annualized growth rate of more than 20% over the next decade. In the long-term, the opportunity is expected to be well distributed across key stakeholder companies, which offer services for a diverse range of allogenic and autologous stem cell therapies.

To request a sample copy / brochure of this report, please visit this link

The USD 2.5 billion (by 2030) financial opportunity within the stem cells contract manufacturing market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom the contract manufacturing opportunity related to stem cell therapies can be expected to witness substantial growth due to the rising demand for regenerative medicine across a number of therapeutic areas. The report includes detailed transcripts of discussions held with the following experts:

The research covers detailed profiles of key players (illustrative list provided below) from across key global markets (North America, Europe and Asia-Pacific); each profile provides an overview of the company, information on its service portfolio, manufacturing facilities, financial performance (if available), details on recent developments, as well as an informed future outlook.

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/stem-cell-therapy-contract-manufacturing-market-2019-2030/271.html

or email [emailprotected]

You may also be interested in the following titles:

Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 [emailprotected]

Link:
Contract Manufacturing Services market for stem cells is expected to be worth over USD 2.5 billion by 2030, claims Roots Analysis - Market Research...

INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business UpdateThe company will host an earnings call: Today, August 5 at 4:30 PM…

LA JOLLA, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.(NASDAQ:INMB) (the Company),an immunology company developing treatments that harness the patients innate immune system to fight disease today reported its financial results for the second quarter ended June 30, 2020 and is providing a business update. INmune Bio will hold a conference call today at 4:30 PM Eastern Time. To participate in the call, please dial 415-226-5355 five minutes before the scheduled time.

In the second quarter, and year to date, INmune Bio continued to progress forward with both of our clinical platforms, stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. We announced interim Phase Ib data demonstrating that our Alzheimers Disease candidate, XPro1595, can reduce neuroinflammation. Our progress with XPro1595 supports our overall strategy to create platforms of therapeutics, based on reducing inflammation by targeting the innate immune system to fight disease. We are planning a number of programs employing this approach in NASH, MUC4 expressing HER2+ cancer, ALS and complications of cytokine storm caused by COVID-19. With the Natural Killer Priming platform, we anticipate INKmune Phase I in high-risk MDS to start the second half of this year.

Q2 2020 and Recent Corporate Highlights

DN-TNF PlatformHighlights:

NK Priming Platform Highlights:

Financial Highlights:

Upcoming Milestones:

Financial Results for the Second Quarter Ended June 30, 2020:

Net loss attributable to common stockholders for the second quarter ended June 30, 2020 was $2.1 million, compared to $0.4 million for the quarter ended June 30, 2019.

Research and development expense totaled approximately $0.9 million for the second quarter ended June 30, 2020, compared to approximately $0.6 million during the second quarter ended June 30, 2019.

General and administrative expense was approximately $1.2 million for the quarter ended June 30, 2020, compared to approximately $1.3 million during the second quarter ended June 30, 2019.

As of June 30, 2020, the Company had cash and cash equivalents of approximately $4.8 million with no debt. Subsequent to the quarter end, INmune Bio closed a $25 million gross proceeds public offering of common stock resulting in net proceeds of approximately $23.1 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

As of August 5, 2020, the Company had approximately 13.4 million common shares outstanding.

Earnings Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: August 5, 2020 Time: 4:30 PM Eastern Time Participant Dial-in: 1-415-226-5355

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers (XPro595), and NASH (LIVNate). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patients NK cells to eliminate minimal residual disease in patients with cancer. INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visitwww.inmunebio.com.

Informationabout Forward-Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03, Quellor, XPro1595, LIVNate, and INKmune are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com

Investor Contact: James Carbonara (646) 755-7412 James@haydenir.com

The following table summarizes our results of operations for the periods indicated:

INMUNE BIO, INC.

CONSOLIDATED BALANCE SHEETS (Unaudited)

INMUNE BIO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

INMUNE BIO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Link:
INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business UpdateThe company will host an earnings call: Today, August 5 at 4:30 PM...

Global Cell Analysis Instruments Market (2020 to 2025) – Growth, Trends, and Forecasts – Yahoo Finance UK

Dublin, Aug. 05, 2020 (GLOBE NEWSWIRE) -- The "Cell Analysis Instruments Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The cell analysis instruments market is found increasing due to the growing burden of cancer across the globe and growing biotech industry and research in cell biology.

Cancer is one of the major causes of deaths across the world, with 609,640 victims in 2018, accounting for nearly one in six deaths. The disease has witnessed significant growth in the last few decades and is expected to rise rapidly over the forecast period. According to the National Cancer Institute, there were around 1,735,350 cases of cancer found in the United States during the year 2018.

In addition, WHO has estimated the cancer deaths to increase by 70% over the next two decades, worldwide. The recent years have observed significant inclination by biotech research companies and universities to invest in various single-cell DNA and RNA quantification techniques. Hence, all these factors are found increasing the demand for cell analysis instruments market.

Key Market Trends

Cell Counting Application is Expected to Register a High Growth During the Forecast Period

Cell counting is done to compare different cell populations or responses. It is the fundamental and critical to numerous biological experiments. Cell counting is done by various methods such as automated cell counter, cell cycle analysis, counting cells without cell staining. The cell counting is one of the most important steps in biology and medicine. The cell counting used in medicine to understand the concentration of blood cells which can provide crucial information about the health situation of a person. In cell therapy, it is used to control the dose of cells given to the patient.

Similarly, cell counting is also used to know the concentration of bacteria, viruses and other pathogens in the blood or in other bodily fluids can reveal information about the progress of infectious disease and about the degree of success with which the immune system is dealing with the infection. With the wide applications of cell counting, it is expected that this segment will be witnessing a good CAGR over the forecast period. In addition, increasing burden of life-threatening diseases such as cancer is augmenting the growth of market studied.

North America is Expected to Dominate the Cell Analysis Instruments Market

North America is expected to dominate the market due to the increasing incidences of cancer and increasing corporate & government funding in cell-based research. Being the most developed economy and healthcare industry, the United States has put a benchmark for several markets. Due to the presence of major companies and the strong R&D in biotechnology, the country is witnessing rapid growth in the market studied. The focus of the US government is to further strengthen its healthcare industry, thus there has been a significant increase in the research funding.

Along with that, the country has a large number of laboratories which is augmenting the demand for cell analysis instruments, and ultimately, the US holds the largest share of the market owing to the high demand.

Competitive Landscape

The market for cell analysis instruments is moderately competitive and consists of local as well as global players. Developing countries are having a large number of local players that are catering to consumers across laboratories and academia. However, the largest share of the market on the global scale is grabbed by international companies such as Thermo Fisher Scientific, Sartorius AG, Danaher Corporation, etc. With the advancements being done in the biotech industry, it is believed that there will be an emergence of the new players in the future.

Reasons to Purchase this report:

Story continues

Key Topics Covered:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Cancer Incidence Rate 4.2.2 Growing Biotech Industry and Research in Cell Biology 4.3 Market Restraints 4.3.1 High Cost of Cell Analysis 4.3.2 Complex Regulatory Scenario 4.4 Porter's Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Product 5.1.1 Instruments 5.1.1.1 Microscopes 5.1.1.2 Flow Cytometers 5.1.1.3 Spectrophotometers 5.1.1.4 Cell Microarrays 5.1.1.5 Others 5.1.2 Consumables 5.2 By Application 5.2.1 Cell Counting 5.2.2 Cell Viability 5.2.3 Cell Identification 5.2.4 Target Identification 5.2.5 PCR 5.2.6 Others 5.3 By End-User 5.3.1 Academic and Research Institutes 5.3.2 Pharmaceutical & Biotechnology Companies 5.3.3 Others 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 Australia 5.4.3.5 South Korea 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle-East and Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle-East and Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Becton Dickinson and Company 6.1.2 Sartorius AG 6.1.3 Danaher Corporation 6.1.4 Merck KGaA 6.1.5 Thermo Fisher Scientific 6.1.6 Miltenyi Biotec 6.1.7 STEMCELL Technologies 6.1.8 Terumo BCT 6.1.9 Promega Corporation 6.1.10 GE Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/rmp0ll

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

View original post here:
Global Cell Analysis Instruments Market (2020 to 2025) - Growth, Trends, and Forecasts - Yahoo Finance UK

HKUMed researchers first discovered SARS-CoV-2 infects human neural progenitor cells and brain organoids – Mirage News

Researchers at the School of Biomedical Sciences, the Department of Microbiology and the Department of Medicine, LKS Faculty of Medicine of The University of Hong Kong (HKUMed) collaborated with researchers at the Institute of Synthetic Biology of Chinese Academy of Sciences-Shenzhen Institutes of Advanced Technology to conduct a study on SARS-CoV-2 infection of human neural progenitor cells and brain organoids. The results are now published in life sciences journal Cell Research [link to the publication].

Background

Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1 as resulted in over 17 million confirmed cases and more than 686,703 deaths across 218 countries and geographical regions as of 3 August 2020. This novel coronavirus primarily causes respiratory illness with clinical manifestations largely resembling those of SARS. However, neurological symptoms including headache, anosmia, ageusia, confusion, seizure and encephalopathy have also been frequently reported in COVID-19 patients. In a study of 214 hospitalized COVID-19 patients in Wuhan, Mainland China, neurologic findings were reported in 36.4% of patients, and were more commonly observed in patients with severe infections (45.5%)2. Similarly, a study from France reported neurologic findings in 84.5% (49/58) of COVID-19 patients admitted to hospital3. Most Importantly, a recent study in Germany demonstrated that SARS-CoV-2 RNA could be detected in brain biopsies in 36.4% (8/22) of fatal COVID-19 cases4, which highlights the potential for viral infections in the human brain. To date, there has been no direct experimental evidence of SARS-CoV-2 infection in the human central nervous system (CNS).

Research Findings

To explore the direct involvement of SARS-CoV-2 in the CNS in physiologically relevant models, the research team assessed SARS-CoV-2 infection in induced pluripotent stem cells (iPSCs)-derived human neural progenitor cells (hNPCs), neurospheres and brain organoids.

The results demonstrated that iPSC-derived hNPCs were permissive to SARS-CoV-2 infection, but not SARS-CoV infection. Extensive protein expression and infectious viral particles were detected in neurospheres and brain organoids infected with SARS-CoV-2, which suggest SARS-CoV-2 can productively infect the human brain. Importantly, SARS-CoV-2 infection in 3D human brain organoids was localized to TUJ1 (neuronal marker)- and NESTIN (NPC marker)-positive cells, suggesting SARS-CoV-2 could directly target cortical neurons and NPCs.

Overall, our study provides the first evidence of direct SARS-CoV-2 infection in human brain organoids, which contributes to our understanding on the pathogenesis of neurological complications in COVID-19, said Professor Huang Jian-dong, L & T Charitable Foundation Professor in Biomedical Sciences, School of Biomedical Sciences, HKUMed, who led the research.

He also pointed out that the Zika virus that re-emerged in 2015 is also well recognized to target neural progenitor cells in the human brain, leading to microcephaly and severe developmental defects in the fetus and other neurological anomalies in adults. The research team suggests that the chronic or long-term consequence of SARS-CoV-2 infection on the CNS should be closely monitored.

About the Research Team

The research was led by Prof Huang Jian-dong, L & T Charitable Foundation Professor in Biomedical Sciences, School of Biomedical Sciences, HKUMed, in collaboration with Dr Zhang Bao-zhong at the Institute of Synthetic Biology of Chinese Academy of Sciences-Shenzhen Institutes of Advanced Technology; Prof Ivan Hung Fan-ngai, Ru Chien and Helen Lieh Professor in Health Sciences Pedagogy, Chief of Infectious Diseases Division and Clinical Professor at Department of Medicine, Assistant Dean (Admissions) of HKUMed; Dr Chu Hin, Research Assistant Professor, Department of Microbiology, HKUMed; Dr Jasper Chan Fuk-woo, Clinical Assistant Professor, Department of Microbiology, HKUMed and Prof Yuen Kwok-yung, Henry Fok Professor in Infectious Diseases and Chair of Infectious Diseases, Department of Microbiology, HKUMed.

Acknowledgments

This work was supported by Health and Medical Research Fund (COVID190117) from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, the Shenzhen Peacock Plan Team Project, Shenzhen Science and Technology Innovation Committee Basic Science Research Grant.

More here:
HKUMed researchers first discovered SARS-CoV-2 infects human neural progenitor cells and brain organoids - Mirage News

Electromedical Inc. Accelerates Corporate Expansion and Product DevelopmentAnnounces the Opening of First European Office For the Development of New…

SCOTTSDALE, Ariz., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTC:ELCQ) (the Company), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that its Director of Technology, Mr. Petar Gajic, will establish a research and development office in Belgrade, Europe for the creation of new products and technologies.

Matthew Wolfson, CEO of ELCQ, commented, Petar Gajic is currently in Belgrade, Serbia right in the middle of Europe (Nikola Teslas birth-place), a perfect place for engineering talents. He is establishing our first European office for the development of our POD device along with other exciting technologies. Mr. Gajic brings years of experience working in computer technology, electrical engineering and programming fields and later as Director of Technology for Electromedical for the past 15 years.

Commenting further, Mr. Wolfson said, Peter was instrumental in the development of the Wellness Pro product line and now we look forward for him to oversee and manage the opening of our first technology office in Europe, and overseeing the development of our NEW Wellness Pro POD . This will help us expedite the development of the Wellness Pro POD at more cost-efficient rates, so that we can bring the product to market ahead of schedule. We continue to execute on our Product Development roadmap, and are excited to begin our European expansion. Mr Gajic will also coordinate research efforts and will be more efficient in working with Nazarbayev University. https://www.businesswire.com/news/home/20200423005273/en/Electromedical-Technologies-Announces-Research-Collaboration-Nazarbayev-University

Finally, Mr Wolfson said, Pharmacology has dominated most, if not all, medical treatments for centuries. Todays pharmacology is coupled with precision surgery, biologicals, stem cell regeneration technologies and personalized medicine based on genomics. Meanwhile, it is also evident that drugs have their limitations and can cause harmful side effects. There are alternative medical treatments such as electrical bio-modulation therapies, that are just now coming to the forefront of treating pain. Our goal is to bring awareness to the masses of the Wellness Pro product line and its powerful and effective treatments. Aside from establishing our EU research and development under Mr. Gajics direction, we are also focused on the continuing effects of the COVID -19 pandemic on opioid use and abuse here and elsewhere. As reported by CNN, the U.S. Opioid crisis will worsen during and after the pandemic, and we think this is a significant time for our company and products to really offer a drug free alternative and solution without the harmful side effects of opioids. https://www.cnn.com/2020/05/07/health/opioid-epidemic-covid19-pandemic-trnd/index.html

About Electromedical Technologies:

Headquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The companys current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, visit https://electromedtech.com

Safe Harbor Statement:

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Electromedical Technologies, Inc. Matthew Wolfson Tel: 1.888.880.7888 email: ceo@electromedtech.com https://electromedtech.com

Read more here:
Electromedical Inc. Accelerates Corporate Expansion and Product DevelopmentAnnounces the Opening of First European Office For the Development of New...